ICS-formoterol as reliever (MART — maintenance and reliever therapy) preferred across GINA tracks 1 and 2; step up for uncontrolled disease; assess biomarkers (eos, FeNO, IgE) for biologic candidates in severe asthma.
Authored pathway active · asthma-in-adults.outpatient
ICS-formoterol as reliever (MART — maintenance and reliever therapy) preferred across GINA tracks 1 and 2; step up for uncontrolled disease; assess biomarkers (eos, FeNO, IgE) for biologic candidates in severe asthma.
Guidelines: GINA 2025 Global Strategy for Asthma Management and Prevention · ATS/ERS 2024 Severe Asthma Guideline · NAEPP EPR-4 Focused Updates
Phenotypes (4)
- Mild Intermittent Asthma (GINA Step 1-2)
- Moderate Persistent Asthma (GINA Step 3-4)
- Severe Eosinophilic Asthma
- Acute Severe Asthma Exacerbation
Pathway-scoped symptom and exam intake
Test this pathway's ROS and differential links
Uses LR engine pulm.asthma.core.v1, then routes suggested engines into the workspace.
19-panel workspace
asthma-in-adults · OutpatientStart patient workup
Open a scratch or linked encounter, add active problems, then keep labs, fluids, acid-base, and electrolyte tools beside the main workspace instead of losing context.
Encounter and problems
No encounter open. Add a problem to create a scratch encounter when none is open.
Multi-window tools
Unified
labs + fluids + acid-base
Labs
fast lab analyzer
Fluid
resuscitation and balance
Electrolytes
Na/K/Mg/Phos/Ca
ABG/VBG
compensation and mixed disorders
Popular entry points
6 quick-startsOr jump straight to the atlas
The Engine Atlas covers every authored disease package with setting chips and pathway badges. Open any engine to load its 19-panel workspace, backed by phenotype-aware reasoning and monitored by the Flow Assistant.